biostudies-literatureUnknown10(12)Shao C<h4>Background</h4>Protein kinase membrane associated tyrosine/threonine 1 (<i>PKMYT1</i>) regulates cell cycle and is a part of DNA damage repair (DDR)-related signaling. Recent studies have identified a role for <i>PKMYT1</i> in tumor immunity and DDR. Thus, we initiated this study aiming to characterize the molecular and immunological portrait of <i>PKMYT1</i> in cancer.<h4>Methods</h4>Transcriptomic data extrapolated from Genotype-Tissue Expression (GTEx), The Cancer Genome Atlas (TCGA), and Cancer Cell Line Encyclopedia (CCLE) datasets were used to determine the mRNA expression levels of <i>PKMYT1</i>. <i>PKMYT1</i> mRNA expression status was correlated with patients' prognosis as well as immune neoantigens, and immune checkpoints in 34 different tumors. The Tumor Immune Estimation Resource (TIMER) dataset was used to analyze immune infiltrating scores.<h4>Results</h4><i>PKMYT1</i> mRNA is differentially expressed in common tumors and high expression levels of <i>PKMYT1</i> mRNA is associated with poor prognosis except for malignant thymoma (THYM). In addition, <i>PKMYT1</i> mRNA expression was correlated with tumor-infiltrating immune cells particularly in lung squamous cell carcinoma, esophageal carcinoma, THYM, and lung adenocarcinoma. An upregulation of immune checkpoints and neoantigens was observed in tumors with a high <i>PKMYT1</i> mRNA expression. Data from gene set enrichment analysis (GSEA) revealed that <i>PKMYT1</i> is involved in tumor immunogenicity, metabolism, and cell cycle progression.<h4>Conclusions</h4><i>PKMYT1</i> is differentially expressed in various cancers and exerts an important effect on tumor immunity and progression. The <i>PKMYT1</i> gene holds the potential as a new potential biomarker. Therefore, further studies are clearly needed to elaborate our findings.Translational lung cancer research4600-4616https://www.ebi.ac.uk/biostudies/studies/S-EPMC8743528biostudies-literatureThe DNA damage repair-related gene <i>PKMYT1</i> is a potential biomarker in various malignancies.PMC8743528Guo KMolnar TFKocher FBarr MPSeeber AMa ZHan JWang YYan XShao CPan MNavarro AfalseThe DNA damage repair-related gene <i>PKMYT1</i> is a potential biomarker in various malignancies.<h4>Background</h4>Protein kinase membrane associated tyrosine/threonine 1 (<i>PKMYT1</i>) regulates cell cycle and is a part of DNA damage repair (DDR)-related signaling. Recent studies have identified a role for <i>PKMYT1</i> in tumor immunity and DDR. Thus, we initiated this study aiming to characterize the molecular and immunological portrait of <i>PKMYT1</i> in cancer.<h4>Methods</h4>Transcriptomic data extrapolated from Genotype-Tissue Expression (GTEx), The Cancer Genome Atlas (TCGA), and Cancer Cell Line Encyclopedia (CCLE) datasets were used to determine the mRNA expression levels of <i>PKMYT1</i>. <i>PKMYT1</i> mRNA expression status was correlated with patients' prognosis as well as immune neoantigens, and immune checkpoints in 34 different tumors. The Tumor Immune Estimation Resource (TIMER) dataset was used to analyze immune infiltrating scores.<h4>Results</h4><i>PKMYT1</i> mRNA is differentially expressed in common tumors and high expression levels of <i>PKMYT1</i> mRNA is associated with poor prognosis except for malignant thymoma (THYM). In addition, <i>PKMYT1</i> mRNA expression was correlated with tumor-infiltrating immune cells particularly in lung squamous cell carcinoma, esophageal carcinoma, THYM, and lung adenocarcinoma. An upregulation of immune checkpoints and neoantigens was observed in tumors with a high <i>PKMYT1</i> mRNA expression. Data from gene set enrichment analysis (GSEA) revealed that <i>PKMYT1</i> is involved in tumor immunogenicity, metabolism, and cell cycle progression.<h4>Conclusions</h4><i>PKMYT1</i> is differentially expressed in various cancers and exerts an important effect on tumor immunity and progression. The <i>PKMYT1</i> gene holds the potential as a new potential biomarker. Therefore, further studies are clearly needed to elaborate our findings.2021-01-01T00:00:00Z2021 Dec2025-04-05T14:35:38.552Z2025-04-05T14:35:38.552ZS-EPMC87435283507076410.21037/tlcr-21-973